



Havn Life Announces Management Change

July 2, 2021

Vancouver, BC - Havn Life Sciences Inc. (CSE: [HAVN](#)) (OTC: [HAVLF](#)) (FSE: [5NP](#)) (the "Company" or "Havn Life") announces that Mr. Gordon Clissold has joined the Company as Chief Financial Officer.

Mr. Clissold is a Chartered Professional Accountant who has been recognized for his contributions to the accounting profession. He has over 20 years of experience as an operational and financial manager, in both public and private companies, with career experience spanning technology, manufacturing, wholesale distribution, and professional services. His management competencies encompass organizational leadership, strategic planning, corporate finance, financial modelling, ERP and financial systems implementation, internal control development, and due diligence for mergers and acquisitions. Mr. Clissold has led the international expansion of companies and has established a reputation for being able to identify the talent necessary to build high-performing teams.

The Company further announces that Eli Dusenbury will remain on as a consultant providing accounting services on an as needed-basis.

On Behalf of The Board of Directors

Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

HAVN Life Sciences is a Canadian biotechnology company pursuing standardized extraction of psychoactive compounds, the development of natural health products, and innovative mental health treatment to support brain health and enhance the capabilities of the mind. Learn more at: havnlife.com and follow us on [Facebook](#), [Twitter](#), [Instagram](#) and [Youtube](#).

Contact:

Investor Relations: ir@havnlife.com 604 687 7130
Media: savi@emergence-creative.com 647 896-8078

The CSE has not reviewed, approved or disapproved the content of this press release

